Baillie Gifford & CO Stoke Therapeutics, Inc. Transaction History
Baillie Gifford & CO
- $114 Billion
- Q4 2025
A detailed history of Baillie Gifford & CO transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 246,900 shares of STOK stock, worth $6.55 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
246,900Holding current value
$6.55 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding STOK
# of Institutions
161Shares Held
60.8MCall Options Held
563KPut Options Held
101K-
Black Rock Inc. New York, NY5.41MShares$143 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.4MShares$143 Million24.66% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$136 Million1.61% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$123 Million0.89% of portfolio
-
Redmile Group, LLC San Francisco, CA4.18MShares$111 Million10.81% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $1.05B
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...